Insmed reported $-148.3M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
DBV Technologies USD -45.9M 12.42M Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -148.3M 165.88M Mar/2026
Novartis USD 5.41B 431M Mar/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026